Triple-Action antibody takes aim at advanced breast cancer
Disease control
Not yet recruiting
This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…
Phase: PHASE1, PHASE2 • Sponsor: Eddingpharm (Zhuhai) Co., Ltd. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC